Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs T Rowe Price Group Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B), while T Rowe Price Group Inc trades at $100.01 (market cap $21.63B). The key difference: GE HealthCare Technologies Inc. Common Stock is the larger of the two by market cap, and T Rowe Price Group Inc pays the higher dividend (5.13%). Which is the better fit depends on your goals.
| GEHC | TROW | |
|---|---|---|
Market Cap | $31.07B | $21.63B |
Volume | 3,443,020 | 2,302,405 |
Sector | Health | Financials |
52-Week High | $88.16 | $121.68 |
52-Week Low | $59.48 | $86.19 |
Enterprise Value | $39.53B | $18.82B |
Dividend Yield | 0.23% | 5.13% |
Typical Hold Time | — | 115 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
T. Rowe Price (TROW) trades at $99.62, down 4.2% today, with a bearish technical signal despite strong fundamentals including a 29.26% net income margin and 20.1% ROE. The stock shows attractive valuation with a P/E of 10.18 and P/B of 1.97, while recent earnings beat expectations in Q1 and Q2 2026. Assets under management reached $1.90 trillion in August 2026 despite net outflows, and the company maintains a strong dividend history with 40 years of consecutive increases.
TROW presents a value opportunity with solid profitability and dividend stability, though technical weakness and mixed analyst sentiment (21% buy, 63% hold) suggest near-term caution. The consensus price target of $110.50 implies 11% upside potential, but investors face risks from market-sensitive revenue and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
